Salivary Gland Infection Market is segmented By Diagnosis and Assessment (Ultrasound, MRI Scan, CT-Scan), By Treatment (Antibiotic Therapy, Intravenous (IV) Medications, ....
Market Size in USD
CAGR9.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 9.2% |
Market Concentration | Medium |
Major Players | AbbVie Inc., Allergan, AstraZeneca, FUJIFILM Holdings Corporation, GlaxoSmithKline Plc |
The Salivary Gland Infection Market is valued at USD 6.20 billion in 2024 and is expected to reach USD 12.35 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031. The market is driven by the increasing prevalence of salivary gland disorders caused by various factors such as accumulation of debris, presence of bacteria or virus, and tumors.
The market is expected to witness positive growth over the forecast period owing to rising prevalence of infections due to viruses such as mumps virus, increasing consumption of sugary foods and drinks leading to bacterial infections, and growing geriatric population susceptible to chronic disorders affecting salivary glands. However, lack of awareness regarding salivary gland infections especially in developing nations and social stigma associated with chronic infections in some cultures may hamper market growth.